查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2045899

下一代乳癌診斷與篩檢市場—全球產業規模、佔有率、趨勢、機會和預測：按技術、生物標記、癌症亞型、產品、最終用戶、地區和競爭格局分類，2021-2031年

Next-Generation Breast Cancer Diagnostic and Screening Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology, By Biomarker, By Cancer Sub-Type, By Offering, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球下一代乳癌診斷和篩檢市場預計將經歷顯著成長，從 2025 年的 48.1 億美元成長到 2031 年的 88.4 億美元，複合年成長率為 10.68%。

該市場涵蓋基因組分析檢測、液態生物檢體平台和人工智慧成像系統等先進解決方案，所有這些方案旨在提供比傳統方法更高的惡性腫瘤檢測準確率。市場擴張的主要驅動力是全球乳癌發生率的上升以及向個人化醫療的重大轉變，後者需要對腫瘤進行分子水平分析以製定有效的治療策略。例如，美國癌症協會預測，到2025年，美國將有約316,950名女性被診斷出患有侵襲性乳癌，這凸顯了對這種高精度診斷能力的迫切需求。

市場概覽
預測期 2027-2031
市場規模：2025年 48.1億美元
市場規模：2031年 88.4億美元
複合年成長率：2026-2031年 10.68%
成長最快的細分市場 產品
最大的市場 北美洲

市場促進因素

推動市場發展的關鍵因素之一是將人工智慧 (AI) 應用於診斷成像。這從根本上增強了篩檢方案，提高了靈敏度並最佳化了放射科醫生的工作流程。 AI 演算法能夠有效識別緻密乳房組織中的細微惡性腫瘤，並減少假陰性結果，從而顯著提高診斷準確性。真實世界的臨床研究表明，AI 輔助篩檢使乳癌檢出率提高了 17.6%，達到每 1000 名女性 6.7 例。同時，液態生物檢體和非侵入性診斷方法的日益普及正在改變個人化醫療和治療監測。這些基因組分析工具能夠早期檢測循環腫瘤 DNA，使臨床醫生能夠動態調整治療方法，並比傳統影像學方法更早發現復發。鑑於預計到 2050 年全球乳癌病例將達到每年 320 萬例，這一點至關重要。

市場挑戰

採用先進技術的高昂成本對全球下一代乳癌診斷和篩檢市場的成長構成重大挑戰。將基因組分析檢測與人工智慧驅動的成像系統相結合需要大量的資本投入和專門的基礎設施，這對許多醫療機構，尤其是在預算緊張和價格敏感的地區，構成了難以逾越的財務障礙。此外，現有的報銷機制往往不足以涵蓋這些創新解決方案的高昂成本，迫使醫療服務提供者選擇成本較低的傳統方法，儘管這些方法可能具有更高的檢測準確性。這種經濟負擔也延伸到了國家醫療保健系統，乳癌帶來的巨大經濟負擔（預計到2025年將使英國經濟每年損失32億至35億英鎊）往往使各國優先考慮嚴格的成本削減措施，而非採用先進的診斷技術，從而限制了市場擴張和廣泛應用。

市場趨勢

自動乳房超音波（ABUS）在篩檢高密度乳房組織方面的應用正逐漸成為一項重要的診斷標準，有效彌補了傳統乳房X光攝影的不足——後者往往難以檢測到此類組織密度。這種3D容積超音波技術透過使影像擷取不受操作者技能的影響，確保了篩檢的一致性和可重複性。這對於減少假陰性結果和檢測X光系統常漏診的間期癌症至關重要。例如，Invenia ABUS Premium系統與乳房X光攝影合併使用時，癌症檢出率提高了35.7%。同時，造影乳房X光攝影（CEM）的日益普及，為高風險評估和診斷不明的病例提供了一種高靈敏度且經濟高效的磁振造影（MRI）替代方案。 CEM使用碘基造影劑可視化腫瘤血管生成，在病灶檢測方面提供更清晰的影像，並避免了MRI方案相關的高昂操作成本和使用限制。臨床研究表明，電腦能量顯微鏡 (CEM) 能夠準確顯示 90% 的乳癌，而低能量乳房X光攝影只能顯示 10% 的乳癌。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：下一代乳癌診斷與篩檢的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依技術分類（即時PCR、免疫組織化學（IHC）、次世代定序（NGS）、螢光原位雜合反應（FISH）、其他）
    • 透過生物標記（BRCA1/2、ER/PR受體、HER-2等）
    • 癌症亞型（Luminal A、Luminal B、三陰性/基底樣、人類表皮生長因子受體 2 (HER-2) 高表現）
    • 依產品類型（產品、服務）
    • 依最終使用者（醫院/診所、診斷中心/檢驗實驗室、學術/研究機構）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美下一代乳癌診斷與篩檢市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲下一代乳癌診斷與篩檢市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區下一代乳癌診斷與篩檢市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲下一代乳癌診斷和篩檢市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美下一代乳癌診斷與篩檢市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球下一代乳癌診斷與篩檢市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • Abbott Laboratories, Inc.
  • Thermo Fisher Scientific Inc.
  • Hologic, Inc.
  • Siemens Healthineers AG
  • Danaher Corporation
  • Becton, Dickinson and Company
  • Agilent Technologies, Inc.
  • Sysmex Corporation

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 16770

The Global Next-Generation Breast Cancer Diagnostic and Screening Market is poised for substantial growth, projected to increase from USD 4.81 Billion in 2025 to USD 8.84 Billion by 2031, at a CAGR of 10.68%. This market includes advanced solutions like genomic profiling assays, liquid biopsy platforms, and AI-enhanced imaging systems, all designed to offer superior precision in detecting malignancies compared to traditional methods. Market expansion is primarily fueled by the rising global prevalence of breast cancer and a significant shift towards personalized medicine, which demands molecular-level tumor analysis for effective treatment strategies. For instance, the American Cancer Society anticipated approximately 316,950 women in the United States would be diagnosed with invasive breast cancer in 2025, highlighting the critical demand for these precise diagnostic capabilities.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 4.81 Billion
Market Size 2031USD 8.84 Billion
CAGR 2026-203110.68%
Fastest Growing SegmentProducts
Largest MarketNorth America

Market Driver

A primary market driver is the integration of Artificial Intelligence (AI) in diagnostic imaging, which fundamentally enhances screening protocols by improving sensitivity and optimizing radiologist workflows. AI algorithms effectively identify subtle malignancies and mitigate false negatives in dense breast tissue, thereby significantly boosting diagnostic accuracy; a real-world study showed AI-supported screening increased breast cancer detection rates by 17.6%, achieving 6.7 detections per 1,000 women. Simultaneously, the increasing adoption of liquid biopsy and non-invasive diagnostics is transforming personalized medicine and treatment monitoring. These genomic tools enable early detection of circulating tumor DNA, allowing clinicians to dynamically tailor therapies and detect recurrence sooner than traditional imaging, proving vital as global breast cancer cases are projected to rise to 3.2 million annually by 2050.

Market Challenge

The high implementation costs associated with advanced technologies represent a significant challenge to the growth of the Global Next-Generation Breast Cancer Diagnostic and Screening Market. Integrating genomic profiling assays and AI-driven imaging systems demands substantial capital investment and specialized infrastructure, creating a financial barrier that many healthcare facilities, particularly in price-sensitive regions with stretched budgets, find difficult to overcome. Furthermore, existing reimbursement frameworks often inadequately cover the premium pricing of these innovative solutions, compelling providers to opt for less expensive, traditional methods despite the potential for enhanced detection. This economic strain extends to national health systems, where the substantial financial burden of breast cancer, projected to cost the UK economy between £3.2 billion and £3.5 billion annually in 2025, often prioritizes strict cost-containment measures over the adoption of premium diagnostic technologies, consequently limiting market scaling and widespread implementation.

Market Trends

The implementation of Automated Breast Ultrasound (ABUS) for screening dense breast tissue is becoming a key diagnostic standard, effectively addressing the limitations of conventional mammography, which often struggles with such tissue density. This volumetric 3D ultrasound technology ensures consistent, reproducible screening by de-linking image acquisition from operator skill, crucial for reducing false negatives and detecting interval cancers missed by X-ray systems; the Invenia ABUS Premium system, for example, detected 35.7% more cancers when used with mammography. Concurrently, the rising utilization of Contrast-Enhanced Mammography (CEM) offers a highly sensitive and cost-effective alternative to Magnetic Resonance Imaging (MRI) for high-risk assessments and inconclusive diagnoses. CEM utilizes iodinated contrast agents to visualize tumor neovascularization, providing superior clarity for lesion detection without the considerable operational costs or accessibility constraints of MRI protocols, with clinical studies indicating it successfully depicted 90% of breast cancers compared to just 10% with low-energy mammograms.

Key Market Players

  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • Abbott Laboratories, Inc.
  • Thermo Fisher Scientific Inc.
  • Hologic, Inc.
  • Siemens Healthineers AG
  • Danaher Corporation
  • Becton, Dickinson and Company
  • Agilent Technologies, Inc.
  • Sysmex Corporation

Report Scope

In this report, the Global Next-Generation Breast Cancer Diagnostic and Screening Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Next-Generation Breast Cancer Diagnostic and Screening Market, By Technology

  • Real-Time PCR
  • Immunohistochemistry (IHC)
  • Next-Generation Sequencing (NGS)
  • Fluorescence In-Situ Hybridization (FISH)
  • Others

Next-Generation Breast Cancer Diagnostic and Screening Market, By Biomarker

  • BRCA1/2
  • ER/PR Receptors
  • HER-2
  • Others

Next-Generation Breast Cancer Diagnostic and Screening Market, By Cancer Sub-Type

  • Luminal A
  • Luminal B
  • Triple Negative/Basal Like
  • Human Epidermal Growth Factor Receptor 2 (HER-2) Enriched

Next-Generation Breast Cancer Diagnostic and Screening Market, By Offering

  • Products
  • Services

Next-Generation Breast Cancer Diagnostic and Screening Market, By End User

  • Hospitals and Clinics
  • Diagnostic Centers and Reference Labs
  • Academic & Research Institutes

Next-Generation Breast Cancer Diagnostic and Screening Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Next-Generation Breast Cancer Diagnostic and Screening Market.

Available Customizations:

Global Next-Generation Breast Cancer Diagnostic and Screening Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Next-Generation Breast Cancer Diagnostic and Screening Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Technology (Real-Time PCR, Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), Fluorescence In-Situ Hybridization (FISH), Others)
    • 5.2.2. By Biomarker (BRCA1/2, ER/PR Receptors, HER-2, Others)
    • 5.2.3. By Cancer Sub-Type (Luminal A, Luminal B, Triple Negative/Basal Like, Human Epidermal Growth Factor Receptor 2 (HER-2) Enriched)
    • 5.2.4. By Offering (Products, Services)
    • 5.2.5. By End User (Hospitals and Clinics, Diagnostic Centers and Reference Labs, Academic & Research Institutes)
    • 5.2.6. By Region
    • 5.2.7. By Company (2025)
  • 5.3. Market Map

6. North America Next-Generation Breast Cancer Diagnostic and Screening Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Technology
    • 6.2.2. By Biomarker
    • 6.2.3. By Cancer Sub-Type
    • 6.2.4. By Offering
    • 6.2.5. By End User
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Technology
        • 6.3.1.2.2. By Biomarker
        • 6.3.1.2.3. By Cancer Sub-Type
        • 6.3.1.2.4. By Offering
        • 6.3.1.2.5. By End User
    • 6.3.2. Canada Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Technology
        • 6.3.2.2.2. By Biomarker
        • 6.3.2.2.3. By Cancer Sub-Type
        • 6.3.2.2.4. By Offering
        • 6.3.2.2.5. By End User
    • 6.3.3. Mexico Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Technology
        • 6.3.3.2.2. By Biomarker
        • 6.3.3.2.3. By Cancer Sub-Type
        • 6.3.3.2.4. By Offering
        • 6.3.3.2.5. By End User

7. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Technology
    • 7.2.2. By Biomarker
    • 7.2.3. By Cancer Sub-Type
    • 7.2.4. By Offering
    • 7.2.5. By End User
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Technology
        • 7.3.1.2.2. By Biomarker
        • 7.3.1.2.3. By Cancer Sub-Type
        • 7.3.1.2.4. By Offering
        • 7.3.1.2.5. By End User
    • 7.3.2. France Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Technology
        • 7.3.2.2.2. By Biomarker
        • 7.3.2.2.3. By Cancer Sub-Type
        • 7.3.2.2.4. By Offering
        • 7.3.2.2.5. By End User
    • 7.3.3. United Kingdom Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Technology
        • 7.3.3.2.2. By Biomarker
        • 7.3.3.2.3. By Cancer Sub-Type
        • 7.3.3.2.4. By Offering
        • 7.3.3.2.5. By End User
    • 7.3.4. Italy Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Technology
        • 7.3.4.2.2. By Biomarker
        • 7.3.4.2.3. By Cancer Sub-Type
        • 7.3.4.2.4. By Offering
        • 7.3.4.2.5. By End User
    • 7.3.5. Spain Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Technology
        • 7.3.5.2.2. By Biomarker
        • 7.3.5.2.3. By Cancer Sub-Type
        • 7.3.5.2.4. By Offering
        • 7.3.5.2.5. By End User

8. Asia Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Technology
    • 8.2.2. By Biomarker
    • 8.2.3. By Cancer Sub-Type
    • 8.2.4. By Offering
    • 8.2.5. By End User
    • 8.2.6. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Technology
        • 8.3.1.2.2. By Biomarker
        • 8.3.1.2.3. By Cancer Sub-Type
        • 8.3.1.2.4. By Offering
        • 8.3.1.2.5. By End User
    • 8.3.2. India Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Technology
        • 8.3.2.2.2. By Biomarker
        • 8.3.2.2.3. By Cancer Sub-Type
        • 8.3.2.2.4. By Offering
        • 8.3.2.2.5. By End User
    • 8.3.3. Japan Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Technology
        • 8.3.3.2.2. By Biomarker
        • 8.3.3.2.3. By Cancer Sub-Type
        • 8.3.3.2.4. By Offering
        • 8.3.3.2.5. By End User
    • 8.3.4. South Korea Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Technology
        • 8.3.4.2.2. By Biomarker
        • 8.3.4.2.3. By Cancer Sub-Type
        • 8.3.4.2.4. By Offering
        • 8.3.4.2.5. By End User
    • 8.3.5. Australia Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Technology
        • 8.3.5.2.2. By Biomarker
        • 8.3.5.2.3. By Cancer Sub-Type
        • 8.3.5.2.4. By Offering
        • 8.3.5.2.5. By End User

9. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Technology
    • 9.2.2. By Biomarker
    • 9.2.3. By Cancer Sub-Type
    • 9.2.4. By Offering
    • 9.2.5. By End User
    • 9.2.6. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Technology
        • 9.3.1.2.2. By Biomarker
        • 9.3.1.2.3. By Cancer Sub-Type
        • 9.3.1.2.4. By Offering
        • 9.3.1.2.5. By End User
    • 9.3.2. UAE Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Technology
        • 9.3.2.2.2. By Biomarker
        • 9.3.2.2.3. By Cancer Sub-Type
        • 9.3.2.2.4. By Offering
        • 9.3.2.2.5. By End User
    • 9.3.3. South Africa Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Technology
        • 9.3.3.2.2. By Biomarker
        • 9.3.3.2.3. By Cancer Sub-Type
        • 9.3.3.2.4. By Offering
        • 9.3.3.2.5. By End User

10. South America Next-Generation Breast Cancer Diagnostic and Screening Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Technology
    • 10.2.2. By Biomarker
    • 10.2.3. By Cancer Sub-Type
    • 10.2.4. By Offering
    • 10.2.5. By End User
    • 10.2.6. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Technology
        • 10.3.1.2.2. By Biomarker
        • 10.3.1.2.3. By Cancer Sub-Type
        • 10.3.1.2.4. By Offering
        • 10.3.1.2.5. By End User
    • 10.3.2. Colombia Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Technology
        • 10.3.2.2.2. By Biomarker
        • 10.3.2.2.3. By Cancer Sub-Type
        • 10.3.2.2.4. By Offering
        • 10.3.2.2.5. By End User
    • 10.3.3. Argentina Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Technology
        • 10.3.3.2.2. By Biomarker
        • 10.3.3.2.3. By Cancer Sub-Type
        • 10.3.3.2.4. By Offering
        • 10.3.3.2.5. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Next-Generation Breast Cancer Diagnostic and Screening Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Exact Sciences Corporation
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. F. Hoffmann-La Roche Ltd.
  • 15.3. Abbott Laboratories, Inc.
  • 15.4. Thermo Fisher Scientific Inc.
  • 15.5. Hologic, Inc.
  • 15.6. Siemens Healthineers AG
  • 15.7. Danaher Corporation
  • 15.8. Becton, Dickinson and Company
  • 15.9. Agilent Technologies, Inc.
  • 15.10. Sysmex Corporation

16. Strategic Recommendations

17. About Us & Disclaimer